根据证监会《上市公司独立董事管理办法》《上海证券交易所股票上市规则》 《上海证券交易所上市公司自律监管指引第 1 号——规范运作》等要求，浙江圣 达生物药业股份有限公司（以下简称"公司"）董事会，就公司在任独立董事胡 国华、李永泉、陈希琴的独立性情况进行评估并出具如下专项意见： 经核查独立董事胡国华、李永泉、陈希琴的任职经历以及签署的相关自查文 件，上述人员未在公司担任除独立董事以外的任何职务，也未在公司主要股东公 司担任任何职务，与公司以及主要股东之间不存在利害关系或其他可能妨碍其进 行独立客观判断的关系，因此，公司董事会认为，公司独立董事符合《上市公司 独立董事管理办法》《上海证券交易所上市公司自律监管指引第 1 号——规范运 作》等规定中对独立董事独立性的相关要求。 浙江圣达生物药业股份有限公司董事会 二〇二五年四月二十四日 浙江圣达生物药业股份有限公司董事会 关于独立董事独立性自查情况的专项意见 ...

浙江天册律师事务所 关于 浙江圣达生物药业股份有限公司 浙江省杭州市杭大路 1 号黄龙世纪广场 A 座 11 楼邮编 310007 电话：0571 8790 111 传真：0571 8790 1500 https://www.tclawfirm.com/ 调整 2024 年员工持股计划之 法律意见书 | 释 义 1 | | | --- | --- | | 第一部分 | 引言 2 | | 第二部分 | 正文 4 | | 一、关于本次员工持股计划调整前已经取得的批准和授权 4 | | | 二、关于调整本次员工持股计划的批准和授权 5 | | | 三、关于本次员工持股计划调整的内容 5 | | | 四、结论意见 11 | | 法律意见书 释 义 | 本所/天册 | 浙江天册律师事务所（特殊普通合伙） | | --- | --- | | 公司、上市公司、圣达生物 | 浙江圣达生物药业股份有限公司，股票代码 | | | 603079 | | 本计划、本次员工持股计划 | 浙江圣达生物药业股份有限公司 年员工持 2024 | | | 股计划 | | 《公司法》 | 《中华人民共和国公司法》 | | 《证券法》 | 《中华 ...

| 持有数量(万股) 名称 | | 占总股本比例 (%) | 增减情况(万 股) | | --- | --- | --- | --- | | 浙江圣达集团有限公司 | 4537.58 | 26.51 | 不变 | | 天台万健投资发展中心(有限合伙) | 3128.75 | 18.28 | -148.36 | | 浙江鸿博企业管理有限公司 | 1201.99 | 7.02 | 不变 | | 朱勇刚 | 409.24 | 2.39 | 不变 | | 陆庆贵 | 125.67 | 0.73 | 新进 | | 浙江银轮机械股份有限公司 | 118.88 | 0.69 | 不变 | | 万家中证1000指数增强A | 80.16 | 0.47 | 新进 | | MORGAN STANLEY & CO. INTERNATIONAL PLC. | 55.69 | 0.33 | -6.96 | | 蒋锡才 | 54.00 | 0.32 | 新进 | | 陈蓓文 | 51.50 | 0.30 | 新进 | | 较上个报告期退出前十大股东有 | | | | | UBS AG | 153.18 | 0.89 | 退出 | | 高 ...

证券代码：603079 证券简称：圣达生物 公告编号：2025-022 浙江圣达生物药业股份有限公司 重要内容提示： 一、 召开会议的基本情况 (一)股东大会类型和届次 股东大会召开日期：2025年5月26日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 方式 (五)网络投票的系统、起止日期和投票时间。 2024年年度股东大会 关于召开2024年年度股东大会的通知 (四)现场会议召开的日期、时间和地点 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 召开的日期时间：2025 年 5 月 26 日 13 点 30 分 召开地点：浙江省天台县福溪街道始丰东路 18 号,公司会议室 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 5 月 26 日 至2025 年 5 月 26 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间 ...

证券代码：603079 证券简称：圣达生物 公告编号：2025-015 浙江圣达生物药业股份有限公司 第四届监事会第十五次会议决议公告 表决结果：同意3票，反对0票，弃权0票。 本议案尚需提交公司股东大会审议。 (二) 审议通过《2024年度公司财务决算》 表决结果：同意3票，反对0票，弃权0票。 本议案尚需提交公司股东大会审议。 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 浙江圣达生物药业股份有限公司（以下简称"公司"）第四届监事会第十 五次会议（以下简称"本次会议"）于2025年4月24日在公司会议室以现场表决 方式召开。本次会议已于2025年4月14日以电子邮件方式通知全体监事。本次会 议由公司监事会主席徐涵先生主持，应到监事3人，实到监事3人。 本次会议的通知、召开、表决程序符合《中华人民共和国公司法》等法律、 行政法规、部门规章、规范性文件及《浙江圣达生物药业股份有限公司章程》 （以下简称"《公司章程》"）的有关规定，会议形成的决议合法有效。 二、监事会会议审议情况 (一) 审议通过《20 ...

证券代码：603079 证券简称：圣达生物 公告编号：2025-014 浙江圣达生物药业股份有限公司 第四届董事会第十六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 浙江圣达生物药业股份有限公司（以下简称"公司"）第四届董事会第十 六次会议（以下简称"本次会议"）于2025年4月24日在公司会议室以现场表决 方式召开。本次会议已于2025年4月14日以电子邮件方式通知全体董事、监事及 高级管理人员。本次会议由公司董事长洪爱女士主持，应到董事9人，实到董事 9人；公司监事、高级管理人员列席了本次会议。 本次会议的通知、召开、表决程序符合《中华人民共和国公司法》、《浙 江圣达生物药业股份有限公司章程》（以下简称"《公司章程》"）等有关规 定，会议形成的决议合法有效。 二、董事会会议审议情况 (一) 审议通过《2024年度董事会工作报告》 表决结果：同意9票，反对0票，弃权0票。 本议案尚需提交公司股东大会审议。 (二) 审议通过《2024年度总经理工作报告》 表决结果：同意9票，反对0票， ...

证券代码：603079 证券简称：圣达生物 公告编号：2025-016 浙江圣达生物药业股份有限公司 关于公司2024年度利润分配方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 2024年度利润分配方案为：不派发现金红利，不送红股，不以资本公积 转增股本。 公司2024年实施股份回购，以现金方式回购股份视同现金分红的金额为 13,113,100.00元（不含印花税、交易佣金等交易费用）。 本次利润分配方案已经公司第四届董事会第十六次会议和第四届监事会 第十五次会议审议通过，尚需提交公司2024年年度股东大会审议。 公司不触及《上海证券交易所股票上市规则（2024年4月修订）》（以下 简称《股票上市规则》）第9.8.1条第一款第（八）项规定的可能被实施其他风 险警示的情形。 一、利润分配方案内容 （一）利润分配方案的具体内容 经天健会计师事务所（特殊普通合伙）审计，公司2024年度合并报表中实 现 归 属 于 母 公 司 股 东 的 净 利 润 29,424,490.05 元 ， 母 公 司 实 现 ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 203,225,651.02, representing a year-on-year increase of 9.95% compared to CNY 184,829,589.97 in the same period last year[4]. - Net profit attributable to shareholders of the listed company reached CNY 21,709,484.85, a significant increase of 469.35% from CNY 3,813,060.72 in the previous year[4]. - The basic and diluted earnings per share were both CNY 0.13, reflecting a 550.00% increase from CNY 0.02 in the same period last year[5]. - The weighted average return on equity increased by 1.4 percentage points to 1.71% compared to 0.31% in the previous year[5]. - Total revenue for Q1 2025 reached ¥203,225,651.02, an increase of 9.5% compared to ¥184,829,589.97 in Q1 2024[20]. - Net profit for Q1 2025 was ¥23,418,911.36, significantly up from ¥5,303,881.02 in Q1 2024, representing a growth of 341.5%[21]. - Operating profit for Q1 2025 was ¥27,633,346.93, compared to ¥7,505,502.29 in Q1 2024, indicating a substantial increase[21]. - Basic earnings per share for Q1 2025 were ¥0.13, compared to ¥0.02 in Q1 2024, indicating a significant improvement[22]. Cash Flow and Assets - The net cash flow from operating activities was negative at CNY -21,121,737.08, worsening from CNY -7,787,016.92 in the same period last year[4]. - Cash flow from operating activities was ¥190,106,736.12 in Q1 2025, up from ¥178,966,766.36 in Q1 2024, reflecting a growth of 6.3%[24]. - The total cash outflow from operating activities was $228,918,640.38, compared to $198,347,829.36 previously, resulting in a net cash flow from operating activities of -$21,121,737.08, worsening from -$7,787,016.92[25]. - The company's current assets totaled approximately 663.38 million RMB, a decrease from 708.77 million RMB on December 31, 2024[15]. - The company's cash and cash equivalents decreased from approximately 315.62 million RMB to 244.56 million RMB over the same period[15]. - The ending cash and cash equivalents balance was $222,366,162.95, down from $247,275,484.71, reflecting a decrease of approximately 10.1%[26]. Investments and Fundraising - The company plans to issue up to 51,356,687 A-shares, raising a total of no more than 500 million RMB, to invest in the production of 3 billion soft capsules and 3 billion solid preparations, as well as a project for an annual output of 20,000 tons of D-isoascorbic acid and its sodium salt[13]. - The company has adjusted its fundraising amount for the A-share issuance from 500 million RMB to 267.61 million RMB[13]. - Cash inflow from investment activities totaled $88,480,311.40, significantly up from $23,717,143.12, indicating a substantial increase in investment recovery[25]. - The cash outflow from investment activities was $131,675,436.43, compared to $108,287,452.50, leading to a net cash flow from investment activities of -$43,195,125.03, an improvement from -$84,570,309.38[25]. Shareholder Information - The major shareholders include Zhejiang Shengda Group Co., Ltd. with a 26.51% stake and Tian Tai Wan Jian Investment Development Center with an 18.28% stake[10]. - The employee stock ownership plan aims to hold up to 872,500 shares, with a total funding not exceeding 4.9995 million RMB[14]. - The stock purchase price for the employee stock ownership plan is set at 5.73 RMB per share[14]. - The company has not yet implemented the employee stock ownership plan as of March 31, 2025[14]. Research and Development - Research and development expenses rose to ¥10,162,625.24 in Q1 2025, up from ¥7,896,868.68 in Q1 2024, reflecting a 28.7% increase[21]. - The company has not disclosed any new product developments or market expansion strategies in this report[8]. Asset Changes - The total assets at the end of the reporting period were CNY 1,806,478,130.51, a slight increase of 1.19% from CNY 1,785,311,152.08 at the end of the previous year[5]. - The company’s fixed assets decreased slightly from approximately 432.02 million RMB to 424.76 million RMB[16]. - The company’s intangible assets increased from approximately 225.58 million RMB to 227.64 million RMB[16]. - Total liabilities decreased to ¥499,084,898.78 from ¥501,336,831.71, showing a reduction of 0.5%[18]. - Shareholders' equity increased to ¥1,307,393,231.73 from ¥1,283,974,320.37, marking a growth of 1.8%[18].

Financial Performance - The net profit attributable to the parent company for 2024 is RMB 29,424,490.05, with the parent company achieving a net profit of RMB 13,084,701.15[6]. - The company's operating revenue for 2024 reached ¥827,401,959.68, representing a year-on-year increase of 13.75% compared to ¥727,405,727.98 in 2023[25]. - The net profit attributable to shareholders for 2024 was ¥29,424,490.05, a significant recovery from a loss of ¥54,062,928.21 in 2023[25]. - The net cash flow from operating activities increased by 129.55% to ¥147,878,103.30 in 2024, up from ¥64,421,472.79 in 2023[25][27]. - The company's total assets as of the end of 2024 were ¥1,785,311,152.08, reflecting a 3.85% increase from ¥1,719,185,557.88 in 2023[26]. - Basic earnings per share for 2024 improved to ¥0.17, compared to a loss of ¥0.32 per share in 2023[26]. - The weighted average return on equity for 2024 was 2.35%, up from -4.19% in 2023, indicating improved profitability[26]. Dividend Policy - The company plans to distribute no cash dividends, no bonus shares, and no capital reserve conversion to share capital for the 2024 fiscal year[7]. - The total cash dividend amount accounted for 44.57% of the net profit attributable to ordinary shareholders in the consolidated financial statements, which was CNY 29,424,490.05[150]. - The company has established a three-year shareholder dividend return plan for 2023-2025, emphasizing reasonable returns to investors[146]. Risks and Challenges - The company faces significant risks including product price fluctuations, raw material price volatility, high customer concentration, exchange rate fluctuations, and changes in the macroeconomic environment[10]. - Raw material price volatility poses a significant risk to the company's profitability, as raw materials constitute a large portion of production costs[115]. - The sales revenue from the top five customers accounted for 20.47%, 21.09%, 24.07%, and 31.99% of total revenue in 2021, 2022, 2023, and 2024 respectively, indicating a high customer concentration risk[116]. - The company is exposed to risks from macroeconomic changes, which could impact consumer demand and overall profitability[117]. Market and Product Development - The company focused on enhancing its product sales structure, particularly in the pharmaceutical-grade vitamin sector and biological preservatives, contributing to revenue growth[25]. - The company plans to continue expanding its market presence in high-value products, particularly in biological preservatives and functional ingredients[25]. - The company completed registrations for biotin in India, EU CEP, and South Korea, laying the groundwork for further market expansion[36]. - The company is focusing on cost reduction and efficiency improvement through innovative production and technology upgrades[35]. Research and Development - The company is committed to increasing R&D investment and maintaining close cooperation with universities and research institutions[38]. - Research and development expenses amounted to 43.76 million yuan, reflecting a 1.95% increase from the previous year[55]. - The company has 48 ongoing research projects and has obtained 8 national patents during the reporting period[53]. - The company is focusing on synthetic biology research and has built platforms for strain construction and fermentation[53]. Environmental Compliance - The company has implemented a comprehensive environmental management system, certified by ISO14001, ensuring compliance with pollution control regulations[181]. - The company has no reported administrative penalties for environmental issues during the reporting period, indicating strong compliance[178]. - The company is committed to environmental compliance, conducting at least 3 manual samples for various pollutants, including toluene and sulfuric acid, every six months[170]. - The company has established a dedicated environmental protection department to oversee compliance and pollution prevention efforts[181]. Corporate Governance - The board of directors consists of 9 members, including 3 independent directors, complying with legal and regulatory requirements[120]. - The company has held 3 shareholder meetings during the reporting period, ensuring compliance with legal procedures and equal rights for all shareholders[119]. - The company has implemented a transparent performance evaluation and incentive mechanism for its directors and senior management[120]. - All directors participated in the board meetings, with no instances of continuous absence from meetings[133]. Employee Engagement - The company has a total of 1,035 employees, including 711 production personnel and 172 technical personnel[142]. - The company approved the 2024 Employee Stock Ownership Plan, which aims to enhance employee engagement and retention[154]. - The company has implemented a dual-channel administrative and technical salary management assessment model to enhance employee motivation and responsibility[143]. Strategic Initiatives - The company plans to invest a total of RMB 499.87 million in the first phase of the "Vitamin Series Products and Raw Material Drug Industry Upgrade Project"[106]. - The company is exploring acquisition opportunities to enhance its product portfolio, targeting a deal worth up to 100 million[127]. - The management team emphasized a focus on sustainability initiatives, allocating 10 million towards eco-friendly practices[130].

一、 会议召开和出席情况 证券代码：603079 证券简称：圣达生物 公告编号：2025-013 浙江圣达生物药业股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 (一)股东大会召开的时间：2025 年 4 月 23 日 重要内容提示： (二)股东大会召开的地点：浙江省天台县福溪街道始丰东路 18 号,公司会议室 本次会议是否有否决议案：无 二、 议案审议情况 (一)非累积投票议案 1、 议案名称：《关于延长公司向特定对象发行 A 股股票股东大会决议有效期的 议案》 审议结果：通过 表决情况： | 股东类型 | 同意 | | 反对 | | 弃权 | | | --- | --- | --- | --- | --- | --- | --- | | | 票数 | 比例（%） | 票数 | 比例 | 票数 | 比例 | | | | | | （%） | | （%） | | A 股 | 92,732,653 | 99.6215 | 229,344 | 0.2463 | 122,900 | ...